Autoantibodies to OxLDL Are Decreased in Individuals With Borderline Hypertension

Hypertension

Volumn 33, Issue 1, 1999, Pages 53-59

  Wu, Ruihua ^a   de Faire, Ulf ^a   Lemne, Carola ^a   Witztum, Joseph L ^a   Frostegard, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; ATHEROSCLEROSIS; B SCAN; CAROTID ARTERY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HYPERTENSION; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT;

ANTIGEN-ANTIBODY COMPLEX; ARTERIOSCLEROSIS; AUTOANTIBODIES; BLOOD PRESSURE; CARDIOLIPINS; CAROTID ARTERY DISEASES; CHEMILUMINESCENT MEASUREMENTS; DATA INTERPRETATION, STATISTICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HUMANS; HYPERTENSION; IMMUNOASSAY; IMMUNOGLOBULIN G; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION;

EID: 0032950484     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/01.HYP.33.1.53     Document Type: Article

References (49)

1. MacMahon SW, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke and coronary heart disease: part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765-769.
2. Lemne C, Jogestrand T, de Faire U. Carotid intima-media thickness and plaque in borderline hypertension. Stroke. 1995;26:34-39.
3. Dzielak DJ. The immune system and hypertension. Hypertension. 1992;19:136-144.
4. Fu ML. Do immune system changes have a role in hypertension? J Hypertens. 1995;13:1259-1265.
5. Frostegard J, Lemne C, Andersson B, Kiessling R, de Faire U. Association of serum antibodies to heat shock protein 65 with borderline hypertension. Hypertension. 1997;29:40-44.
6. Ross R. The pathogenesis of atherosclerosis-a perspective for the 1990s. Nature. 1993;362:801-809.
7. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest. 1991;64:5-15.
8. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Pathol. 1989;135:169-175.
9. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
10. Yla-Herttuala S, Palinski W, Butler S, Picard S, Steinberg D, Witztum J. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb. 1994;14:32-40.
11. Salonen JT, Yla-Herttuala S, Yamamoto R, Butler S, Korpela H, Salonen R, Nyssonen K, Palinski W, Witztum JL. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
12. Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol. 1995;15:441-445.
13. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, Finardi G, Bellomo G. LDL oxidation in patients with severe carotid atherosclerosis: a study of in vitro and in vivo oxidation markers. Arterioscler Thromb. 1994;14:1892-1899.
14. Virella G, Virella I, Leman RB, Pryor MB, Lopes-Virella MF. Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res. 1993;23:95-101.
15. Boullier A, Hamon M, Walters-Laporte E, Martin-Nizard F, Mackereel R, Fruchart JC, Bertrand M, Duriez P. Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease. Clin Chim Acta. 1995;238:1-10.
16. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A. 1995;92:821-825.
17. Ameli S, Hultgardh-Nilsson A, Regnstrom J, Calara F, Yano J, Cervek B, Shah PK, Nilsson J. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol. 1996;16:1074-1079.
18. Nilsson J, Calara F, Regnstrom J, Hultgardh-Nilsson A, Ameli S, Cercek B, Shah PK. Immunization with homologous oxidized low density lipoprotein reduces neointimal formation after balloon injury in hypercholesterolemic rabbits. J Am Coll Cardiol. 1997;30:1886-1891.
19. Lemne C, Hamsten A, Karpe F, Nilsson-Ehle P, de Faire U. Dyslipoproteinemic changes in borderline hypertension. Hypertension. 1994;24:605-610.
20. Lemne C, Lindvall K, Georgiades A, Fredriksson M, de Faire U. Structural cardiac changes in relation to 24 hour ambulatory blood pressure levels in borderline hypertension. J Intern Med. 1995;238:49-57.
21. Wu R, Lefvert AK. Autoantibodies against oxidized low density lipoprotein (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin Exp Immunol. 1995;102:174-180.
22. Palinski W, Yla-Herttuala S, Rosenfeld S, Butler SA, Socher S, Parthasarathy S, Curtiss LK, Witztum JL. Antisera and monoclonal antibodies specific for epitopes generated during the oxidative modification of low density lipoprotein. Arteriosclerosis. 1990;10:325-335.
23. Harris EN, Gharavi AE, Patel SP, Hughes GRV. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol. 1986;68:215-222.
24. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, Witztum JL. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice: demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest. 1996;98:800-814.
25. Horkko S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch W, Palinski W, Witztum JL. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. J Clin Invest. 1996;98:815-825.
26. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, Palinski W, Schwenke D, Solomon RG, Sha W, Subbanagounder G, Fogelman AM, Berliner J. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence of their presence in vivo. J Biol Chem. 1997;272:13597-13607.
27. Young SG, Smith RS, Hogle DM, Curtiss LK, Witztum JL. Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. Clin Chem. 1986;32:1484-1490.
28. Frostegard J, Wu R, Gillis-Haegerstrand C, Lemne C, de Faire U. Antibodies to endothelial cells in borderline hypertension. Circulation. 1998;98:1092-1098.
29. Frostegard J, Nilsson J, Haegerstrand A, Hamsten A, Wigzell H, Gidlund M. Oxidized low-density lipoprotein induces differentiation and adhesion of human monocytes and the monocytic cell line U937. Proc Natl Acad Sci U S A. 1990;87:904-908.
30. Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK, Warrier RR, Pham N, Fogelman AM, Modlin RL. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest. 1996;97:2130-2138.
31. Frostegard J, Wu R, Giscombe R, Holm G, Lefvert AK, Nilsson J. Induction of T cell activation by oxidized low density lipoprotein. Arterioscler Thromb. 1992;12:461-467.
32. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A. 1995;92:3893-3897.
33. Huang YH, Ronnelid J, Frostegard J. Oxidized LDL induces enhanced antibody formation and MHC class II dependent IFN-gamma production in lymphocytes from healthy individuals. Arterioscler Thromb Vasc Biol. 1995;15:1577-1583.
34. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Bamshad B, Esterson M, Fogelman AM. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest. 1990;85:1260-1266.
35. Frostegard J, Haegerstrand A, Gidlund M, Nilsson J. Biologically modified low density lipoprotein increases the adhesive properties of vascular endothelial cells. Atherosclerosis. 1991;90:119-126.
36. Watson AD, Navab M, Hama SY, Sevanian A, Prescott AM, Stafforini DM, McIntyre TM, La Du BN, Fogelman A, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995;95:774-782.
37. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM. Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest. 1995;96:2322-2330.
38. Frostegard J, Huang YH, Ronnelid J, Schafer-Elinder L. PAF and oxidized LDL induce immune activation by a common mechanism. Arterioscler Thromb Vasc Biol. 1997;17:963-968.
39. Kosugi K, Morel DW, DiCorleto PE, Chisolm GM. Toxicity of oxidized low-density lipoprotein to cultured fibroblasts is selective for S phase of the cell cycle. J Cell Physiol. 1987;130:311-320.
40. Coffey MD, Cole RA, Colles SM, Chisom GM. In vitro cell injury by oxidized low density lipoprotein involves lipid hydroperoxide-induced formation of alkoxyl, lipid and peroxyl radicals. J Clin Invest. 1995;96:1866-1873.
41. Hughes H, Mathews B, Lenz ML, Guyton JR. Cytotoxicity of oxidized LDL to porcine aortic smooth muscle cells is associated with the oxysterols 7-ketocholesterol and 7-hydroxycholesterol. Arterioscler Thromb Vasc Biol. 1994;14:1177-1185.
42. Fyfe AI, Qiao JH, Lusis AH. Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet. J Clin Invest. 1994;94:2516-2520.
43. Dansky HM, Charlton SA, Harper MM, Smith JD. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1997;94:4642-4646.
44. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiated atherosclerosis in ApoE knock-out mice. J Clin Invest. 1997;99:2752-2761.
45. Nagano H, Lippy P, Taylor MK, Hasegawa S, Stinn JL, Becker G, Tilney NL, Mitchell RN. Coronary arteriosclerosis after T-cell-mediated injury in transplanted mouse hearts: role of interferon-gamma. Am J Pathol. 1998;152:1187-1197.
46. Emeson EE, Shen ML, Bell CG, Qureshi A. Inhibition of atherosclerosis in CD4 T cell ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol. 1996;149:675-685.
47. Roselaar SE, Schonfeld G, Daugherty A. Enhanced development of atherosclerosis in cholesterol-fed rabbits by suppression of cell-mediated immunity. J Clin Invest. 1995;96:1389-1394.
48. Emeson EE, Shen ML. Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. Am J Pathol. 1993;142:1906-1915.
49. Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G, Bellomo G. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. J Hypertens. 1995;13:129-138.